1mmv: Difference between revisions
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
[[Image:1mmv.gif|left|200px]] | [[Image:1mmv.gif|left|200px]] | ||
<!-- | |||
The line below this paragraph, containing "STRUCTURE_1mmv", creates the "Structure Box" on the page. | |||
You may change the PDB parameter (which sets the PDB file loaded into the applet) | |||
or the SCENE parameter (which sets the initial scene displayed when the page is loaded), | |||
or leave the SCENE parameter empty for the default display. | |||
| | --> | ||
| | {{STRUCTURE_1mmv| PDB=1mmv | SCENE= }} | ||
}} | |||
'''Rat neuronal NOS heme domain with NG-propyl-L-arginine bound''' | '''Rat neuronal NOS heme domain with NG-propyl-L-arginine bound''' | ||
| Line 30: | Line 27: | ||
[[Category: Li, H.]] | [[Category: Li, H.]] | ||
[[Category: Poulos, T L.]] | [[Category: Poulos, T L.]] | ||
[[Category: | [[Category: Heme-enzyme]] | ||
[[Category: | [[Category: Nitric oxide synthase]] | ||
[[Category: | [[Category: Oxydoreductase]] | ||
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Sat May 3 01:26:05 2008'' | |||
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on | |||
Revision as of 01:26, 3 May 2008
Rat neuronal NOS heme domain with NG-propyl-L-arginine bound
OverviewOverview
Isoform-specific nitric-oxide synthase (NOS) inhibitors may prove clinically useful in reducing the pathophysiological effects associated with increased neuronal NOS (nNOS) or inducible NOS (iNOS) activity in a variety of neurological and inflammatory disorders. Analogs of the NOS substrate L-arginine are pharmacologically attractive inhibitors because of their stability, reliable cell uptake, and good selectivity for NOS over other heme proteins. Some inhibitory arginine analogs show significant isoform selectivity although the structural or mechanistic basis of such selectivity is generally poorly understood. In the present studies, we determined by x-ray crystallography the binding interactions between rat nNOS and N5-(1-imino-3-butenyl)-L-ornithine (L-VNIO), a previously identified mechanism-based, irreversible inactivator with moderate nNOS selectivity. We have also synthesized and mechanistically characterized several L-VNIO analogs and find, surprisingly, that even relatively minor structural changes produce inhibitors that are either iNOS-selective or non-selective. Furthermore, derivatives having a methyl group added to the butenyl moiety of L-VNIO and L-VNIO derivatives that are analogs of homoarginine rather than arginine display slow-on, slow-off kinetics rather than irreversible inactivation. These results elucidate some of the structural requirements for isoform-selective inhibition by L-VNIO and its related alkyl- and alkenyl-imino ornithine and lysine derivatives and may provide information useful in the ongoing rational design of isoform-selective inhibitors.
About this StructureAbout this Structure
1MMV is a Single protein structure of sequence from Rattus norvegicus. Full crystallographic information is available from OCA.
ReferenceReference
Structural characterization and kinetics of nitric-oxide synthase inhibition by novel N5-(iminoalkyl)- and N5-(iminoalkenyl)-ornithines., Bretscher LE, Li H, Poulos TL, Griffith OW, J Biol Chem. 2003 Nov 21;278(47):46789-97. Epub 2003 Sep 5. PMID:12960153 Page seeded by OCA on Sat May 3 01:26:05 2008